Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE(R)

NEW BRUNSWICK, N.J., April 29, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the United States Patent and Trademark Office (PTO) regarding the reexamination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE® (infliximab) in which the PTO maintained its rejection of the patent.  Based on the receipt of today's action, the company's subsidiary, Janssen Biotech, Inc., will have until June 12 to file a notice of appeal to the PTO's Patent Trial and Appeal Board and plans to do so.

Currently the '471 patent expires in September 2018.  Patent '471 remains a valid and enforceable patent as it undergoes reexamination at the PTO.  Janssen Biotech will continue to defend its intellectual property rights, and if necessary, will pursue all available appeals.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc. and Johnson & Johnson. Risks and uncertainties include, but are not limited to, challenges to the coverage and/or validity of the company's patents. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.)

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.